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Available online 2 November 2016Background: The recently diagnosed leukodystrophy Hypomyelination with Brain stem and Spinal cord involve-
ment and Leg spasticity (HBSL) is caused by mutations of the cytoplasmic aspartyl-tRNA synthetase gene DARS.
The physiological role of DARS in translation is to accurately pair aspartate with its cognate tRNA. Clinically, HBSL
subjects show adistinct pattern of hypomyelination and develop progressive leg spasticity, variable cognitive im-
pairment and epilepsy. To elucidate the underlying pathomechanism,we comprehensively assessed endogenous
DARS expression in mice. Additionally, aiming at creating the ﬁrst mammalian HBSL model, we genetically
engineered and phenotyped mutant mice with a targeted Dars locus.
Results: DARS, although expressed in all organs, shows a distinct expression pattern in the adult brain with little
immunoreactivity inmacroglia but enrichment in neuronal subpopulations of the hippocampus, cerebellum, and
cortex. Within neurons, DARS is mainly located in the cell soma where it co-localizes with other components of
the translation machinery. Intriguingly, DARS is also present along neurites and at synapses, where it potentially
contributes to local protein synthesis. Dars-null mice are not viable and die before embryonic day 11. Heterozy-
gous mice with only one functional Dars allele display substantially reduced DARS levels in the brain; yet these
mutants show no gross abnormalities, including unchangedmotor performance. However, we detected reduced
pre-pulse inhibition of the acoustic startle response indicating dysfunction of attentional processing in Dars+/−
mice.
Conclusions: Our results, for the ﬁrst time, show an in-depth characterization of the DARS tissue distribution in
mice, revealing surprisingly little uniformity across brain regions or between the major neural cell types. The
complete loss of DARS function is not tolerated inmice suggesting that the identiﬁed HBSLmutations in humans
retain some residual enzyme activity. The mild phenotype of heterozygous Dars-null carriers indicates that even
partial restoration of DARS levels would be therapeutically relevant. Despite the fact that they do not resemble
the full spectrum of clinical symptoms, the robust pre-pulse inhibition phenotype of Dars+/−micewill be instru-
mental for future preclinical therapeutic efﬁcacy studies. In summary, our data is an important contribution to a
better understanding of DARS function and HBSL pathology.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
Translation of mRNA into protein is an evolutionary conserved fea-
ture of life. The role of aminoacyl-tRNA synthetases (ARSs) in transla-
tion is to accurately pair tRNAs with their corresponding amino acids
ensuring the ﬁdelity of protein synthesis. Eukaryotic cells possess 19 cy-
tosolic ARSs, which are obligatorily expressed enzymes. Mutations in
cytosolic ARSs (denoted by their single letter amino acid), as well as in
some of the mitochondrial ARSs (Scheper et al., 2007; Steenweg et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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central nervous system with white matter abnormalities as a common
feature (Antonellis and Green, 2008; Yao and Fox, 2013). The broad
spectrum of neurogenic disorders comprises Charcot-Marie-Tooth neu-
ropathies (GARS, YARS, AARS, and KARS) (Yao and Fox, 2013), inherited
peripheral neuropathies (HARS) (Safka Brozkova et al., 2015), spinal
muscular atrophy (GARS) (Antonellis et al., 2003), nonsyndromic hear-
ing loss (KARS) (Santos-Cortez et al., 2013), cerebral-cerebellar atrophy
(QARS) (Zhang et al., 2014), and hypomyelination (RARS) (Wolf et al.,
2014).
The DARS gene encodes the cytoplasmic aspartyl-tRNA synthetase,
which functions as a dimer and consists of anN-terminal anticodon rec-
ognition domain and a C-terminal catalytic domain. Homozygous as
well as compound heterozygous point mutations of the DARS gene
that confer non-synonymous amino-acid substitutions to highly con-
served residues in the catalytic domain cause the white matter disorder
Hypomyelination with Brain stem and Spinal cord involvement and Leg
spasticity (HBSL) (Taft et al., 2013; Wolf et al., 2015). HBSL belongs to a
group of debilitating rare diseases, termed childhood leukodystrophies.
These inheritedmyelin diseases are associatedwith substantialmorbid-
ity and mortality in children with a population incidence of 1 in 7600
live births (Bonkowsky et al., 2010). Most HBSL patients develop pro-
gressive leg spasticity, cerebellar dysfunction, nystagmus, variable cog-
nitive impairment, and epilepsy. MRI shows hypomyelination of the
entire supratentorial white matter, the cerebellar peduncles, the anteri-
or brainstem, and the dorsal columnsof the spinal cord (Taft et al., 2013;
Wolf et al., 2015). It remains unclear how DARS mutations cause this
speciﬁc pattern of hypomyelination, which differs from other cytoplas-
mic ARS deﬁciencies. Interestingly, HBSL bears a striking resemblance to
Leukoencephalopathy with Brain stem and Spinal cord involvement
and elevated Lactate (LBSL), which is caused by missense mutations of
themitochondria-speciﬁc DARS2 gene (Scheper et al., 2007), suggesting
that these two diseases might share a common underlying molecular
pathology. However, the two enzymes are not functionally redundant
as DARS2-deﬁciency in mice is embryonically lethal (Dogan et al.,
2014). So far HBSL animal models were not available precluding inves-
tigations into bothDARS gene function and the pathomechanismunder-
lying the complex pathology.
Here, we characterize the general Dars expression in wildtype mice
at the mRNA and protein level. Dars, although expected to be essential
in all cells, shows a very distinct expression pattern in the brain, with
enrichment in neuronal subpopulations of the hippocampus, cerebel-
lum, and cortex. We further characterized mice with a Dars-null allele
as a potential model for HBSL using specialized behavioral tests as
well as molecular, biochemical and histological methods. Dars-null
mice die in utero before they reach embryonic day 11. Heterozygous
Dars-null carriers present no overt phenotype and normal locomotor
performance compared to their wildtype littermates, however, these
mice were found to exhibit reduced pre-pulse inhibition of their acous-
tic startle response, indicating impaired attentional processing.
2. Results
2.1. Characteristic Dars expression pattern in mice
Given the lack of knowledge of the regulation ofDars expression and
to advance the understanding of HBSL, we characterized the endoge-
nous Dars expression broadly in the organs of wildtype mice and in
the CNS in particular. Comparing DARS protein levels using Western-
blotting revealed the strongest expression in tissue derived from pe-
ripheral organs such as the lung, kidney, and liver (Fig. 1A and B). In
the CNS, DARS protein levels varied signiﬁcantly between regions
(P= 0.008; one way repeated measures ANOVA) with the highest ex-
pression in the cerebellum followed by the brainstem, hippocampus,
rest of brain (comprising subcortical regions including thalamus and
basal ganglia), and spinal cord. At the mRNA level Dars expression wasenriched in the peripheral tissue of the heart, lung, kidney, liver,muscle,
and sciatic nerve (Fig. 1C). In the CNS, the mRNA levels differed signiﬁ-
cantly between regions (P = 0.007; one way repeated measures
ANOVA) with the highest expression in the cerebellum followed by
the hippocampus, rest of brain, brainstem, spinal cord, and cortex. Con-
sistently, in situ hybridization of DarsmRNA revealed a strong enrich-
ment in the granular layer of the hippocampus and the cerebellum, as
well as in certain areas of the cortex (Fig. 1D; images extracted from
the Allen Mouse Brain Atlas (http://mouse.brain-map.org/)). Immuno-
histochemistry of DARS protein in coronal brain sections showed a
strong enrichment in the granular layer of the hippocampus and the
cerebellum as well as in certain cells of the cortex, the thalamus, and
the brainstem (Fig. 1E). Only a few weak expressing cells were present
in the white matter of the corpus callosum (E1) and striatum (E2).
2.2. Cell type-speciﬁc Dars expression in the CNS
To further discriminatewhich cells expressDars in the CNSwe co-la-
beled mouse brain sections with antibodies for DARS as well as the cell
type speciﬁc markers NeuN (neurons), GstPi (oligodendrocytes), and
GFAP (astrocytes) (Fig. 2). DARS protein is expressed in the cytoplasm
of most neurons (Fig. 2A, D, G) and a fraction of oligodendrocytes (Fig.
2B, E, H).We did not detect DARS immunoreactivity in GFAP positive as-
trocytes (Fig. 2C, F, I). Interestingly, DARS seems to be enriched in cer-
tain neuronal subpopulations in the CA2 region of the hippocampus
(Fig. 2A) and in the cortical layers IV and V (Fig. 2D and Fig. 1D, E).
Analyses of primary hippocampal neurons revealed DARS co-locali-
zation with the ribosomal protein S6 (Fig. 3A), indicating that compo-
nents of the translation machinery are located within the same
subcellular compartment. Co-labeling hippocampal neurons with the
presynaptic marker synaptophysin and the ﬁlamentous actin marker
phalloidin, which is indicative of the postsynaptic compartment, re-
vealed the presence of DARS along neurites as well as at synapses in
vitro (Fig. 3B). To validate the synaptic localization of DARS in vivo we
prepared synaptosomes comprising of both the pre- and the postsynap-
tic compartment aswell as enriched postsynaptic density fractions from
7 month old C57BL/6J mice, and analyzed them by immunoblotting
using antibodies speciﬁc for DARS, synaptophysin (presynaptic mark-
er), PSD95 (postsynaptic marker), and actin. We were able to detect
DARS in synaptosomes as well as in the postsynaptic density fraction,
conﬁrming the localization of DARS in vivo at the synapse, and its pres-
ence at the postsynaptic specialization (Fig. 3C).
2.3. Homozygous Dars deletion is embryonically lethal
To date there is no animal model for HBSL available. In order to es-
tablish a mouse model for HBSL we characterized Dars knock-out mice
obtained from the Center for Animal Resources and Development
(CARD) at Kumamoto University in Japan. Targeting of the Dars locus
was achieved using the pU-17 gene trap vector containing a splicing ac-
ceptor with three stop codons in frame with a β-gal/neomycin-resis-
tance fusion gene (Taniwaki et al., 2005). We performed primer
walking using genomic DNA from heterozygous Dars null carrier mice
and found that the gene trap cassette had integrated into intron 4 of
the Dars locus (Fig. 4A). Integration at this site leads to a truncated
mRNA that only consists of the ﬁrst 320 bp of theDars coding sequence.
If translated, this mRNA would result in a short protein containing only
the initial 106 amino acids. This truncated DARS protein would lack the
entire catalytic domain, normally located between amino acids 174–
497, precluding any residual enzymatic activity. Heterozygous Dars+/−
breeding pairs produced only Dars+/− and Dars+/+ offspring indicating
that homozygous Dars deletion is embryonically lethal (Fig. 4B). To de-
termine at which stage lethality occurs we setup heterozygous timed
mated breeding pairs and terminated the pregnancy for examination
of the embryos. At embryonic days 11 and 14 we found degenerated
embryos in utero (Fig. 4C) that were homozygous Dars null mutants
Fig. 1.DARS expression in the CNS and peripheral organs of adultmice. A. RepresentativeWestern-blot depicting DARS and GAPDH expression across different CNS and peripheral tissues.
B. Quantiﬁcation of DARS protein levels in tissue homogenates by Western-blotting. C. Levels of DarsmRNA in different tissues determined by qRT-PCR. The rest of the brain comprises
subcortical regions including the thalamus and the basal ganglia. Dars mRNA was normalized to Hprt, DARS protein to GAPDH (n = 3). Data represent mean ± SEM. D. In situ
hybridization of DarsmRNA on a sagittal brain section. Insets show areas of the cortex (D1), hippocampus (D2), and cerebellum (D3). Images were extracted from the Allen Mouse
Brain Atlas (http://mouse.brain-map.org/). E. Immunohistochemistry of DARS protein in coronal brain sections. DARS is stained with diaminobenzidine (DAB, brown). Cell bodies are
labeled with Cresyl violet. Insets show the corpus callosum (E1), striatum (E2), hippocampus (E3), thalamus (E4), cerebellum (E5), and brainstem (E6).
26 D. Fröhlich et al. / Neurobiology of Disease 97 (2017) 24–35(Fig. 4D), yet the underdeveloped state of these embryos precluded fur-
ther analyses.
We therefore focused on phenotyping Dars+/−mice in more detail.
Dars mRNA levels in adult heterozygous Dars+/− mice assessed by
primers speciﬁc for exon 13–14 boundary revealed a reduction of
about 50% comparedwithwildtype littermates (Fig. 4E). In comparison,
in 11-day-oldDars−/− embryosDarsmRNAwas virtually absent, except
some residual signal due to contaminating maternal mRNA (Fig. 4F).
2.4. Reduced Dars expression in heterozygous Dars+/−mice
DarsmRNAwas reduced by about 50% in the CNS (Fig. 5A) and in pe-
ripheral organs (Fig. S1A) of Dars+/−mice compared to wildtype litter-
mates as determined by qRT-PCR using TaqMan probes binding at the
exon 13–14 boundary, which is located 3′ of the gene trap integration
site. TaqMan probes binding at the exon 1–2 boundary 5′ of the integra-
tion site revealed that a truncated DarsmRNA is transcribed at slightly
reduced levels compared with controls (Fig. 5B and Fig. S1B). We did
not observe any compensatory upregulation of the mitochondrial
aspartyl-tRNA synthetase Dars2 in Dars+/−mice (Fig. 5C and Fig. S1C).
The reduced DarsmRNA levels led to a robust reduction of about 50–
80% of DARS protein in Dars+/−mice compared to their wildtype litter-
mates assessed by immunoblotting (Fig. 5D, E and Fig. S1D, E). This wasconﬁrmed semi-quantitatively by immunohistochemistry (Fig. 5F, G).
We hypothesized that the robust reduction of DARS protein throughout
all tissues might lead to morphological abnormalities and behavioral
deﬁcits. Therefore, we subjectedDars+/−mice to a comprehensive phe-
notypical analysis.
2.5. Normal CNS morphology and myelination in Dars+/−mice
HBSL patients show severe hypomyelination of the supratentorial
white matter, the cerebellar peduncles, the anterior brainstem, and
the dorsal columns of the spinal cord (Taft et al., 2013; Wolf et al.,
2015). Therefore,we analyzed the generalmorphology andmyelination
of the brain and spinal cord inDars+/−mice. Luxol fast blue-stained cor-
onal sections of brain and spinal cord showed no structural abnormali-
ties or signs of hypomyelination (Fig. 6A, B). Sagittal T2-weighted MRI
images of the spinal cord of Dars+/+ and Dars+/−mice suggested simi-
lar morphology and myelination between genotypes (Fig. 6C) and 3D
modeling of the spinal cord revealed no differences in spinal cord size
(Fig. 6D, E).
In-line with the histological data, the expression of myelin proteins in-
cluding proteolipid protein (PLP), cyclic-nucleotide phosphodiesterase
(CNP), and myelin basic protein (MBP) remained unaltered in the brain
ofDars+/−mice compared towildtype littermates. Immunohistochemistry
Fig. 2. Region and cell type speciﬁc Dars expression. Immunoﬂuorescence of DARS (red) and the cell type speciﬁc markers (green) NeuN (neurons; A, D, G), GstPi (oligodendrocytes; B, E,
H), andGFAP (astrocytes; C, F, I). Nuclei are labeledwith DAPI (blue). Images show coronal sections of the CA3 region of the hippocampus (A–C) and the layers IV to VI of the cortex (D–F).
G–I. Images with higher power illustrate the cytosolic localization of DARS.
27D. Fröhlich et al. / Neurobiology of Disease 97 (2017) 24–35ofPLP (Fig. 7A) andMBP(datanot shown) in coronal brain sections showed
no differences in expression patterns of the major CNS myelin proteins.
Quantitative analysis using qRT-PCR and immunoblotting revealed no sig-
niﬁcant changes in the levels of Plp and Cnp mRNA (Fig. 7B) and PLP/
DM20, CNP, and MBP protein (Fig. 7C, D). Furthermore, heterozygous
Dars+/−mice showedno sign of astrogliosis compared to theirwildtype lit-
termates (Fig. 7E).
2.6. Normal bodyweight, locomotor performance, and explorative behavior
of Dars+/−mice
The clinical spectrum of HBSL patients comprises severe leg spastic-
ity, cerebellar dysfunction, and variable cognitive impairment. To inves-
tigate whether Dars+/− mice model these neurological deﬁcits, they
were subjected to a comprehensive battery of behavioral tests.
Dars+/−mice did not differ in bodyweight compared to wildtype litter-
mates (Fig. 8A) and showed normal locomotor performance assessed in
the open ﬁeld (Fig. 8B) and rotarod (Fig. 8D) tests. To detect putative
subtle abnormalities in motor performance we conducted a compre-
hensive gait analysis. All gait parameters were in the range of wildtype
control animals (Fig. S2). Dars+/− mice had unaltered innate explor-
ative behavior as determined by the distance travelled in the inner com-
partment of an open ﬁeld box (Fig. 8C). Finally, Dars+/− mutants
displayed unchanged anxiety-like behavior in the elevated plus maze
(Fig. 8E) and normal performance in the forced swim test (Fig. 8F).2.7. Impaired attentional processing in Dars+/−mice
To test for more subtle behavioral changes we assessed the acoustic
startle response (ASR) and the pre-pulse inhibition (PPI) of Dars+/−
mice. PPI is a measurement of sensorimotor gating mechanisms and
an impaired PPI indicates deﬁcits in attentional processing (Koch,
1999). First, wemeasured the ASR ofDars+/−mice and observed no dif-
ferences compared to wildtype littermates following exposure to 40ms
white noise pulseswith increasing intensities ranging from60 to 120dB
(Fig. 9A). PPIwas determined by applying a 20ms pre-pulse of 72, 76, or
80 dB 100 ms before the 120 dB startle pulse. This pre-pulse inhibited
the ASR in both genotypes (Fig. 9B). In Dars+/− mice, however, this
PPI was signiﬁcantly reduced by about 20% indicating that their sensori-
motor gating mechanisms are disturbed resulting in impaired atten-
tional processing.3. Discussion
In this study, we demonstrate that the expression of the DARS
aminoacyl-tRNA synthetase, a protein essential for protein synthesis
in all cells, is differentially regulated across different tissues and cell
types. In the CNS, we observed the strongest expression in neurons
of the hippocampus, cerebellum, and cortex where it co-labeled
with components of the translation machinery. Surprisingly, we
Fig. 3. Subcellular localization of DARS protein. A. Cultured primary hippocampal neurons (14 DIV) immunolabelled for DARS (green) and the ribosomal protein S6 (red). B. Primary
hippocampal neurons (14 DIV) were stained for DARS (green). The presynapse was labeled with synaptophysin (red), the postsynapse with phalloidin (blue). Arrowheads indicate
DARS located at individual synapses. C. Western-blot depicting the expression of DARS, the postsynaptic marker PSD95, and the presynaptic marker synaptophysin in total brain
homogenates as well as preparations of synaptosomes (pre- and postsynapse) and postsynaptic densities (PSD; postsynapse) from 7 month old wildtype mice (n= 3).
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and oligodendrocytes show only weak DARS immunoreactivity
compared to neurons. Expression levels in these cell types might be
higher during early stages of development or during repair processes
after brain injury, when there is a high need for newly synthesized
protein. Interestingly, in addition to its somatic localization we
were able to detect DARS along neuronal processes as well as at syn-
apses indicating a putative role in local translation. Local protein
synthesis has several advantages over the transport of pre-existing
proteins, e.g. the translationally silent storage of mRNAs, which can
be used for on-demand synthesis of multiple copies of a protein
and the directed transport of mRNAs to subcellular localizations
using target information in their untranslated region (UTR) (Jung
et al., 2012). Besides the mRNA, the entire translational machinery
has to be present for the de novo synthesis of a protein far away
from the cell body. While local mRNA translation in dendritic spines
mediating synaptic plasticity in response to extrinsic signals is well
accepted (Fernandez-Moya et al., 2014; Liu-Yesucevitz et al., 2011),
the role of local protein synthesis in axons has only recently emerged
(Jung et al., 2012; Piper and Holt, 2004). It has been shown previous-
ly that ribosomal RNA, mRNA, as well as entire ribosomes are present
in dendrites (Fernandez-Moya et al., 2014) and axons (Jung et al.,
2012) including the synapses. Here we reveal that DARS is also a
key component for translation at the synapse, as DARS-dependentcharging of tRNAs is crucial for (local) protein synthesis. Dysregula-
tion of local translation can cause neurodegenerative disorders such
as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis
(ALS), spinocerebellar ataxia (Jung et al., 2012; Liu-Yesucevitz et
al., 2011), and might also contribute to HBSL pathology.
Although DARS is obligatorily expressed in all cell types, HBSL pa-
tients display a distinct pattern of hypomyelination. Here, we dem-
onstrated that oligodendrocytes, the myelin-forming cells of the
CNS, have weak DARS immunoreactivity compared to neurons. Oli-
godendrocytes produce a vast amount of plasma membrane during
themyelination process. Themean surface area of myelin per mature
oligodendrocyte is thousands of times larger than the surface area of
a typical mammalian cell (Lin and Popko, 2009; Pfeiffer et al., 1993).
Therefore, oligodendrocytes have to produce an enormous amount
of myelin proteins (roughly 105 myelin protein molecules per min-
ute (Pfeiffer et al., 1993)), making these cells particularly susceptible
to disruptions of protein synthesis. DARS deﬁciency could either lead
to a general reduction in protein synthesis or permit translational
errors by accepting wrong tRNAs or amino acids, resulting in unfold-
ed or misfolded proteins. Accumulation of misfolded proteins in turn
can cause endoplasmic reticulum (ER) stress leading to the activa-
tion of the unfolded protein response (UPR) (Lin and Popko, 2009).
If the stress is prolonged or the UPR fails to cope with the ER-stress,
apoptosis is triggered and the defective cells are eliminated
Fig. 4.HomozygousDars deletion is embryonically lethal. A. Targeting of the Dars locus was achieved using the pU-17 gene trap vector containing a splicing acceptor (SA) with three stop
codons in frame with a β-gal/neomycin-resistance fusion gene (βgeo). The gene trap cassette integrated into intron 4 of the Dars locus resulting in a disruption of DARS expression. B.
Agarose gel depicting the results of the genotyping PCR using speciﬁc primers for the wt and targeted allele. Breeding Dars+/− animals did not produce any Dars−/− KOs among
Dars+/− and Dars+/+ offspring (n = 23 littermates). C and D. At embryonic days 11 and 14, degenerated Dars−/− embryos (arrowheads) were present in the uterus of pregnant
Dars+/− females mated with Dars+/− males (scale bar 1 mm). E and F. Dars mRNA levels in adult Dars+/+ and Dars+/− mice (E) and 11 day old Dars+/− and Dars−/− embryos (F)
were determined by qRT-PCR and normalized to the housekeeping gene Hprt (n= 3). Data represent mean ± SEM. (⁎p b 0.05, ⁎⁎⁎p b 0.001; Student's t-test).
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ly apparent that ER stress and ER stress-induced apoptosis play an
important role in myelin diseases including multiple sclerosis,
Pelizaeus-Merzbacher disease, vanishing white matter disease, and
Charcot-Marie-Tooth disease (Lin and Popko, 2009). Consistently,
Charcot-Marie-Tooth neuropathies can also be caused by mutations
of other aminoacyl-tRNA synthetases such as GARS, YARS, AARS,
and KARS (Yao and Fox, 2013). Although beyond the scope of this
study, it seems possible that for HBSL, ER-stress caused by mutated
DARS might also essentially contribute to disease progression.
For a better understanding of HBSL and the development of novel
therapeutic strategies we sought to establish Dars-null mice as a
model for HBSL. The embryonic lethality of Dars-null mice, although
underscoring the importance of the DARS aminoacyl-tRNA synthe-
tase, precludes their use as a new transgenic mouse model. DARS
is evolutionarily highly conserved and it has been shown previously
that deletions of the Drosophila ortholog Aats-asp (Stitzinger et al.,
1999) and the S. cerevisiae ortholog DPS1 (Cavarelli et al., 1994)
are not viable. All known DARS mutations causing HBSL in humans
are point mutations located within the catalytic domain of the en-
zyme conferring non-synonymous amino-acid substitutions to
highly conserved residues. Accordingly, our data suggests that the
identiﬁed missense mutations triggering HBSL do not represent a
complete loss-of-function and rather render the mutated DARS pro-
teins functionally impaired with some residual activity. However,
we cannot formally exclude that missense mutations might cause
some gain-of-function effects by affecting putative non-canonical
DARS functions. Interestingly, mutations of the mitochondrial
homolog DARS2 cause the leukodystrophy LBSL with strikingresemblance to HBSL (Scheper et al., 2007), suggesting that both
diseases might share a common etiology. However, the activity of
both enzymes appears to be restricted to their speciﬁc subcellular
compartment with no functional redundancy as both Dars-null
(this study) and Dars2-null (Dogan et al., 2014) mice are embryon-
ically lethal.
Heterozygous Dars-null carriers, which only express half of the
gene dosage, showed half the Dars mRNA levels that translated in
up to 80% loss of DARS protein compared with controls. It will be of
interest to further investigate the relationship between protein
levels and DARS enzymatic activity. How the targeted Dars gene
locus affects the corresponding transcripts and proteins differently
is not known. However, the rather subtle neurological consequences
of deleting one Dars allele may suggest that achieving as little as 20%
of normal protein levels might have a substantial therapeutic effect
in HBSL patients. Potential therapeutic strategies could include
force loading of DARS by nutritional aspartate supplementation,
small molecule pharmacology, and gene therapy. Future studies of
the mouse orthologs of mapped human DARS mutations may yield
insights into the progression of the pathology and hitherto poorly
understood disease mechanism.
In Dars heterozygous mice we did observe an impairment of the
sensorimotor gating mechanism indicating impaired attentional
processing (Koch, 1999). The ASR is mediated by the auditory
nerve, the ventral cochlear nucleus, the dorsal nucleus of the lateral
lemniscus, the caudal pontine reticular nucleus, spinal interneurons,
and spinal motor neurons (Davis et al., 1982). In contrast, PPI of the
ASR is regulated by a complex interplay of fore- and midbrain areas
including the nucleus accumbens, the ventral tegmental area, the
Fig. 5. ReducedDars expression in the CNS of Dars+/−mice. A–C.Dars andDars2mRNA levelswere determined by qRT-PCR using TaqMan probes binding Dars exon 13–14 boundary (A),
Dars exon 1–2 boundary (B), and Dars2 (C). Expression levels were normalized to Hprt (n= 3). D. Western-blots depicting DARS and GAPDH protein levels in different CNS regions of
Dars+/+ and Dars+/−mice. E. Quantiﬁcation of DARS protein levels normalized to GAPDH (n= 3). F and G. Immunohistochemistry for DARS (red) and DAPI (blue) in the cerebellum
(F) and cortex (G) of Dars+/+ and Dars+/−mice. Data represent mean ± SEM (n.s., not signiﬁcant; ⁎p b 0.05, ⁎⁎p b 0.01, ⁎⁎⁎p b 0.001; Student's t-test).
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all areas showed robust reduction of Dars expression in Dars+/−
mice.
While this phenotype does not recapitulate the full spectrum of clin-
ical symptoms, one of the most important ﬁndings of this study is the
identiﬁcation of a behavioral deﬁcit that can be leveraged in subsequent
investigations to assess the efﬁcacy of experimental treatment strate-
gies in the preclinical context. While these initial efforts to model
HBSL in a mammalian system delivered important new knowledge,
our ﬁndings have started to shape the framework for the development
of transgenic mice that more accurately model the genetic mutations
of select HBSL patients.4. Conclusions
Here, we provide an in-depth characterization of the DARS tissue
distribution in mice revealing surprising heterogeneity across brain re-
gions and neural cell types. This knowledge of the DARS expression pat-
tern provides a context for understanding the complex HBSL pathology
and establishes a pathway for developing targeted therapeutic inter-
ventions. The complete loss of DARS function in Dars-null mice is em-
bryonically lethal indicating that HBSL causing point mutations in
humans allow some residual enzyme activity. The mild phenotype ofheterozygous Dars-null mice indicates that even partial restoration of
DARS levels would be therapeutically relevant. The robust pre-pulse in-
hibition of the acoustic startle response in Dars-null carriers, although
not resembling the full clinical spectrum, could be utilized as an end-
point for preclinical therapeutic efﬁcacy studies. In summary, this
study addresses the paucity of knowledge aroundDars gene expression,
cell and systems physiology and associated pathophysiology related to
the leukodystrophy HBSL.
5. Methods
5.1. Ethics statement
All procedures were conducted in accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientiﬁc Purposes,
and were approved by the University of New SouthWales Animal Care
and Ethics Committee (UNSW ACEC approval 14/134B).
5.2. Animals
Targeting of the Dars locus was achieved using the pU-17 gene
trap vector containing a splicing acceptor with three stop codons in
frame with a β-gal/neomycin-resistance fusion gene (Taniwaki et
Fig. 6. Normal CNS morphology and myelination in Dars+/− mice. A and B. Parafﬁn embedded sections from the adult mouse brain (A) and spinal cord (B) were co-stained with
haematoxylin (purple nuclei), eosin (red cytoplasm and extracellular matrix) and Luxol fast blue (blue myelin). Magniﬁcations show the striatum (A1 and A2), the corpus callosum
and the hippocampus (A3 and A4), and the cerebellum (A5 and A6). C. Sagittal T2-weighted MRI images of the spinal cord of Dars+/+ and Dars+/−mice. D and E. 3D modeling of the
spinal cord (D) revealed no differences in spinal cord size (E; n= 5) or morphology. Data represent mean ± SEM (n.s., not signiﬁcant; Student's t-test).
31D. Fröhlich et al. / Neurobiology of Disease 97 (2017) 24–35al., 2005). Following conﬁrmation of germ line transmission at the
Center for Animal Resources and Development at Kumamoto Univer-
sity, Dars heterozygous null embryos were cryopreserved. Subse-
quently, we purchased the embryos and established a colony by
backcrossing Dars+/− mutants into the C57BL/6J background pre-
ceding carrier phenotyping. Genotyping of the Dars locus was per-
formed by PCR (Intron4fwd 5′-ATGTGTCCTGGGATCGTCCA-3′ plus
either Intron4rev 5′-CCCGGACCAGTACAGATGTTAA-3′ for the
wildtype allele or pU-17rev 5′-CCAGACTCTCCCATCCACTACTC-3′ for
the targeted allele).5.3. Cell culture
Primary mouse cortical and hippocampal neurons were prepared as
previously described (Fath et al., 2009). Brieﬂy, E16.5 embryos were
harvested from C57Bl6 mice and hippocampi and cerebral cortices dis-
sected. After enzymatic digestion and sequential titration, dissociated
cultures were plated at a density of 5 K with a co-culture ring of 150 K
cortical neurons on PDL-coated 12 mm coverslips. Cells were main-
tained in neurobasal media supplemented with 2% B27 and 2 mM
Glutamax (Life Technologies, VIC, Australia) at 37 °C and 5% CO2.
Fig. 7. Dars+/−mice show normal myelin protein ratios in the absence of astrogliosis. A. Immunohistochemistry of coronal brain sections displaying PLP (green) in the cortex of Dars+/+
and Dars+/−mice. B–D. Expression pattern of myelin proteins at themRNA (B) and protein (C) levels determined by qRT-PCR andWestern-blotting, respectively. The relative expression
levels of Plp and CnpmRNA in different brain regions normalized toHprt are displayed in B (n=3). C.Western-blot depicting themyelin proteins CNP,MBP, and PLP/DM20, aswell as the
housekeeping protein Tubulin. D. Relative expression of the myelin proteins PLP, MBP, and CNP normalized to Tubulin (n= 3). E. Detection of GFAP immunoreactivity (red) and DAPI
(blue) in coronal brain sections revealed no difference in astrocyte number or activation state in Dars+/−mice compared to Dars+/+ littermates. Data represent mean ± SEM (n.s., not
signiﬁcant; Student's t-test).
Fig. 8. Behavioral phenotyping of Dars+/−mice. A. Body weight of mutants and control littermates at 9 weeks. B and C. Total distance travelled in an open ﬁeld box (B) and distance
travelled in the inner compartment (C) did not vary between genotypes. D. Motor coordination assessed by the rotarod test (average latency to fall over 6 trials on 2 consecutive days;
cut-off time 300 s). E. Time spent in the open arm of an elevated plus maze during a 5 min trial does not vary between genotypes. F. Immobility (ﬂoating) time in a forced swim test
during a 4 min trial. Data represent mean ± SEM (n= 11 (Dars+/+), n= 15 (Dars+/−); age, 9 weeks; n.s., not signiﬁcant; Student's t-test).
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Fig. 9. Impaired attentional processing in Dars+/−mice. A. Dars+/−mice exposed to white noise pulses with increasing intensities (60–120 dB for 40 ms) show a normal acoustic startle
response compared to control littermates. B. Applying a pre-pulse (72, 76, or 80 dB for 20ms) 100ms before the 120 dB pulse inhibits the acoustic startle response in both genotypes. This
pre-pulse inhibition is reduced in Dars+/−mice. Data represent mean ± SEM (n= 19 (Dars+/+) n= 21 (Dars+/−); n.s., not signiﬁcant; ⁎⁎p b 0.01; 2-way ANOVA).
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Primary cells were ﬁxed at 14DIV in 4% paraformaldehyde in PBS for
15 min. After 5 min permeabilization with 0.1% Triton X-100 in PBS,
cells were blocked with 2% fetal bovine serum in PBS for 30 min. Cells
were incubated with primary antibodies rabbit anti-Dars (1:50; Novus
Biological no. NBP1-85937), mouse anti-synaptophysin (1:200; Abcam
no. ab8049), and mouse anti-S6 (1:50; Cell Signaling no. 2317) over-
night at 4 °C. Thiswas followed by 5washeswith PBS and room temper-
ature incubation with donkey anti-mouse Alexa-555, donkey anti-
mouse Alexa-647, donkey anti-rabbit Alexa-488 (Invitrogen, USA),
and phalloidin conjugated to Atto-565 (Atto-Tec, Germany).5.5. Synaptosome preparation
The synaptic plasma membranes were prepared from frozen mouse
brains according to procedures of Monahan andMichel (1987). In brief,
whole brains from 7-month old wildtype C57BL/6J mice were homoge-
nizedwith 6 volumes of buffer A (0.1mMEDTA, 0.1mMEGTA, 0.25mM
phenylmethylsulfonyl ﬂuoride and 1 mM HEPES at pH 7.4) containing
0.32 M sucrose. The homogenate was centrifuged twice at 1000g for
7 min. An aliquot from the combined supernatants was saved as the
brain homogenate and the rest was centrifuged at 38,900g for 45 min.
The pellet was resuspended in 2 volumes of 2 mM Tris-acetate at
pH 8.0 and applied on top of buffer A containing 1.2 M sucrose. After
centrifugation at 230,000g for 45 min, the interface was collected and
applied on top of a layer of buffer A containing 0.9 M sucrose. After cen-
trifugation at 230,000g for 45min, the pellet contains the synaptic plas-
ma membrane fraction. Synaptic junctions (synaptosomes) were
isolated according to procedures of (Chang et al., 1991). Synaptic plas-
ma membranes were homogenized in two volumes of buffer B
(0.2 mM HEPES, 0.05 mM CaCl2, pH 7.4) and centrifuged at 65,000g
for 20min, twice. The pelletwas then resuspended in one volumebuffer
B and2 volumes buffer C (2MHEPES, pH 7.6 in 0.4% TritonX-100), load-
ed onto 1 M sucrose solution, and centrifuged at 85,000g for 1 h. An al-
iquot of the resulting pellet was saved as the synaptosome fraction. The
pure postsynaptic density fraction was prepared by the procedures of
Cohen et al. (1977). In brief, synaptosomes were diluted to 4mg of pro-
tein/ml by solution D (5mMCaCl2 and 6mMTris-HCl at pH 8.1), mixed
with an equal volume of solution E (0.32 M sucrose, 1% (vol/vol) Triton
X-100 and 12 mM Tris-HCl at pH 8.1) incubated on ice for 15 min and
ﬁnally centrifuged at 32,800g for 20min. The resulting pellet was resus-
pended in solution D and applied on top of a step gradient containing
1.0, 1.5 and 2.0 M sucrosewith 1mMNaHCO3 in the 1.0 and 1.5 M frac-
tions. After centrifugation at 200,000g for 2.5 h, the band at the interface
between 1.5 and 2.0 M sucrose layers was collected. The sample was
then mixed with an equal volume of a solution containing 150 mMKCl and 1% Triton X-100 and centrifuged at 200,000g for 20 min. The
resulting pellet was resuspended in 50 μM CaCl2 and 6 mM Tris-HCl at
pH 8.1 and used as the PSD fraction. All fractions were analyzed by
Western-blotting.
5.6. Behavioral testing
Mutants and wildtype controls used in this study were matched for
age and sex. The rotarod testwas performed as described (Mersmann et
al., 2011). Brieﬂy, mice were familiarized with the apparatus (Ugo
Basile, Comerio, Italy) for 4 min at constant speed (4 rpm). In a series
of 3 trials per animal and day, the time themice remained on the accel-
erating roller (4–40 rpm in 4 min) was scored. Cut-off time was set to
5 min. Between trials the animals remained for 30 min in their home
cage. The individual performances were averaged over six trials per-
formed on two consecutive days.
For open ﬁeld testing animals were placed in the center of an open
box (40 × 40× 40 cm3) under bright light conditions (100 lx) andmon-
itored for 30 min. The total distance as well as the distance travelled in
the inner compartment were analyzed using the ANY-maze™ tracking
software (Stoelting, Illinois, USA).
The elevated plusmaze (EPM)was performed as described (Harasta
et al., 2015). Brieﬂy, the EPM consisted of two opposite open arms and
two opposite enclosed arms, interconnected by a central platform (cen-
ter 6 × 6 cm2; open arms, 35 × 6 cm2; closed arms, 35 × 6 × 15 cm3; el-
evation 1m; illumination 40 lx). Micewere placed on themaze, facing a
closed arm and were allowed to freely explore the EPM for 5 min. The
time spent in the open armswas analyzed using the ANY-maze™ track-
ing software (Stoelting, Illinois, USA).
For the forced swim test mice were placed in a glass beaker half-
ﬁlled with 25 °C warm water. In a 4 min trial the immobility time was
determined as the time themouse just ﬂoats on the surface with no ac-
tive swim movement.
Gait analysis was performed using the DigiGait Imaging System
(Mouse Speciﬁcs, Inc., Framingham, MA, USA), which provides an auto-
mated analysis of spatial and temporal gait parameters. Brieﬂy, mice
were placed onto a transparent treadmill with a high-speed digital cam-
eramounted underneath. The speed of the treadmill was set to 20 cm/s.
Several seconds of videowere recorded and analyzed by the software to
yield measures of spatial and temporal gait parameters for each limb.
The acoustic startle response and pre-pulse inhibition (PPI) was de-
termined using the SR-LAB Startle Response System (San Diego Instru-
ments, San Diego, USA) as described previously (Schneider et al.,
2007). To determine the acoustic startle response, mice were exposed
to white noise pulses with increasing intensities (60–120 dB for
40 ms). The cylindrical animal enclosure monitors animal movements
including the startle responsewith a closely coupled accelerometer sen-
sor. PPI was determined in different trials applying 20 ms pre-pulses of
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scribed previously (Schneider et al., 2007). Each trial was repeated 10
times and presented in a pseudorandom order. PPI was calculated as
the percent decrease of the acoustic startle amplitude in trials when
the startle stimulus was preceded by a pre-pulse.
5.7. Magnetic resonance imaging (MRI)
Prior to all in vivoMR imaging procedures, general anesthesia was
induced in an induction chamber with 4% isoﬂurane in oxygen
(1 l/min). Animals were then transferred to the scanner animal bed
and received 2–2.5% isoﬂurane at 0.8 l/min oxygen ﬂow rate through
a nose cone to maintain anesthesia during the scanning procedure. Re-
spiratorymotionwasmonitored during the imaging procedures using a
pressure sensitive pad. Animal body temperature was maintained at
36 °C by a temperature controlled circulating water warming blanket.
In vivo imaging was performed on a 9.4 T Bruker (Ettlingen, Germany)
BioSpec Avance III 94/20 magnetic resonance microimaging system
equipped with BGA-12S HP gradients with maximum strength
660 mT/m and slew rate 4570 Tm/s. A dedicated 23 mm internal diam-
eter quadrature brain volume coil was used for radiofrequency trans-
mission and reception.
5.8. Immunohistochemistry
Mice were anesthetized with pentobarbital and transcardially per-
fused with phosphate buffered saline (PBS), followed by 10% Neutral
buffered formalin (NBF; Sigma). Brains were removed and post-ﬁxed
in NBF (2 h), followed by cryoprotection in 30% sucrose/PBS and cutting
into 40 μm sections using a cryostat (von Jonquieres et al., 2013). Sec-
tions were stored at 4 °C in cryoprotection solution (25% glycerin, 25%
ethylene glycol and 50% PBS). After permeabilization with 0.1% Triton
X-100 in PBS (PBS-Tx) non-speciﬁc binding was blocked with 4% goat
serum in PBS-Tx. Sections were incubated overnight at 4 °C with prima-
ry antibodies in 4% goat serum in PBS-Tx. The following antibodies were
used: rabbit anti-DARS mouse (1:50; Novus Biological no. NBP1-
85937), mouse anti-NeuN (1:500; Millipore no. MAB377), mouse anti-
GFAP (1:500; Cell Signaling no. 3670S), rat anti-PLP clone aa3 (1:10;
gift from Prof. J. Trotter, Mainz, Germany), mouse anti-GstPi (1:200;
BD Biosciences no. 610718). Sections were then washed with PBS and
incubated with appropriate Alexa-488/594 conjugated goat secondary
antibodies (1:400; no. A10667, A11006, A11012, A28181 Thermo Fisher
Scientiﬁc, MA, USA) for 4 h at room temperature in 4% goat serum in
PBS-Tx. Following twowashes in PBS for 10min, sectionswere incubat-
ed in the nuclear dye 4′,6-diamidino-2-phenylindole (DAPI). After an-
other wash in PBS-Tx, sections were mounted in Mowiol (Calbiochem,
Darmstadt, Germany). Fluorescence was visualized using a Zeiss Z1
AxioExaminer NLO710 confocal microscope (Carl Zeiss MicroImaging,
Germany).
Immunoperoxidase labeling using diaminobenzidine (DAB) sub-
strate was performed on coronal sections incubated with biotin conju-
gated goat anti-rabbit secondary antibody (1:250; no. 111-065-003,
Jackson ImmunoResearch, PA, USA). Subsequently, sections were
stained using the DAB substrate kit for peroxidase (Vector Laboratories,
Burlingame, CA, USA, no. SK-4100) according to the manual.
5.9. Haematoxylin & eosin (H&E) and Luxol fast blue (LFB) staining
Mice were deeply anesthetized with a pentobarbital overdose and
transcardially perfused with phosphate buffered saline (PBS), followed
by 10% Neutral buffered formalin (NBF; Sigma). The brains were isolat-
ed and post-ﬁxed for 48 h in NBF. Brains were processed on a Sakura
VIP6 Auto processor followed by embedding in parafﬁn using a Sakura
Tissue-Tek embedder. Tissues were sectioned at 5 μm (Zeiss Hydrax
M40) and stained on a Leica Auto Stainer CV5030 using Harris
haematoxylin and 1% alcoholic eosin. LFB staining was performed onbrain sections using the Kluver and Barrera method (Kluver and
Barrera, 1953). Brieﬂy, parafﬁn sections were dewaxed followed by
treatment in 100% ethanol. Then sections were incubated overnight in
LFB solution (0.1% LFB in 95% ethanol/0.5% acetic acid) at 60 °C. Follow-
ingwashes in 95% ethanol and ddH2O the staining was differentiated in
4% lithium carbonate for 2–4 s. Differentiation commenced in 70% etha-
nol until the greymatter was colorless andwhite matter appeared blue.
Sections were then rinsed in ddH2O before counterstaining with either
preheated 0.025% Cresyl violet acetate solution for 10 min at 37 °C, or
with H&E. Finally, sections were rinsed in ddH2O, dehydrated, cleared
and coverslipped. Stained sections were digitized using Mirax (Zeiss)
or Aperio (Leica) slide scanners.
5.10. Western-blotting
Animals were euthanized at 6 months, different brain regions and
peripheral organs dissected and snap frozen. The tissue was then ho-
mogenized under liquid nitrogen using mortar and pestle. Aliquots
were sonicated in solubilization buffer (30 mM Tris-Cl, pH 7.4, and
5 mMMgCl2 containing 4 mg of CHAPS (Sigma) and 20% glycerol) con-
taining protease inhibitors (Complete, Roche, Mannheim, Germany)
and protein concentration was determined by Bradford assay. 20 μg of
protein wasmixedwith 5× Laemmli reducing sample buffer, separated
by SDS-PAGE, and transferred onto PVDFmembranes (Bio-Rad no. 162-
0177).Membranes were blocked in 4 %milk powder/0.1% Tween in PBS
and probed with the following primary antibodies: rabbit anti-DARS
(1:500; Novus Biological no. NBP1-85937), rabbit anti-GAPDH
(1:5000, Cell Signaling no. 2118S), mouse anti-Actin clone C4
(1:10000, Sigma-Aldrich no. mab1501), mouse anti-CNPase (1:1000,
Abcam no. ab6319), rat anti-MBP (1:1000; Abcam no. ab7349), rat
anti-PLP aa3 (1:200, gift from Prof. J. Trotter, Mainz, Germany), mouse
anti-Tubulin (1:5000; Sigma-Aldrich no. T9026), rabbit anti-PSD95
(1:8000, Sigma-Aldrich no. mab1596), and mouse anti-synaptophysin
(1:8000, Abcam no. ab8049). After washing with 0.1% Tween in PBS
HRP-conjugated secondary antibodies (Dianova, Hamburg, Germany)
were applied. Membranes were developed using Clarity Western ECL
substrate (BioRad no. 170-5060) and imaged using the GelDoc system
(BioRad).
5.11. RNA isolation and qRT-PCR
Animals were euthanized at 6 months, brain and organs dissected, and
snap frozen. The tissue was then homogenized under liquid nitrogen using
mortar and pestle. RNAwas extracted following the manufacturer's instruc-
tions (RNeasy MiniKit, Qiagen no. 74106). DNase treatment was performed
using on-column DNase digestion (RNase-Free DNase Set, Qiagen no.
79254) and RNAwas eluted in 30 μl RNase freewater. Following determina-
tion of RNA content, integrity and purity using the NanoDropND-1000 spec-
trophotometer (Thermo Scientiﬁc), cDNAwas synthesized from500 ng total
RNA using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems no. 4368813) according to the manufacturer's instructions. qRT-
PCR was performed with a StepOnePlus Real-Time PCR system (Applied
Biosystems) utilizing TaqMan assays (Applied Biosystems) for Dars exon 1–
2 (Mm01292106_m1), Dars exon 13–14 (Mm00624185_m1), Dars2
(Mm01296063_m1) Plp (Mm00456892_m1), Cnp (Mm01306640), Hprt
(Mm00446968_m1). Quantitative RT-PCR reactions were performed in trip-
licates. The comparative CTmethod (ΔΔCT) for relative quantiﬁcation of ex-
pressionwas used. Data obtainedwas normalized to the housekeeping gene
Hprt.
5.12. Statistics
Graphs and statistical analyses were performed with the GraphPad
Prism 6 software (La Jolla, CA). Student's t-test, one-way ANOVA, or
two-way ANOVA with correction for multiple comparisons using the
35D. Fröhlich et al. / Neurobiology of Disease 97 (2017) 24–35Bonferroni post-hoc test was used for statistical analysis as appropriate,
subsequent to validation of normal distribution of data.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.10.008.
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